Clinical Trial Update: APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis [Phase 3]

View source ↗

Summary

Phase 3 study of patisiran (ALN-TTR02) for transthyretin-mediated amyloidosis has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloid Neuropathies
• Amyloidosis Hereditary Transthyretin-related
• Familial Amyloid Polyneuropathy
• Hereditary Amyloidosis
• Transthyretin-mediated Amyloidosis

Drugs mentioned

• Patisiran (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis, Amyloidosis, Hereditary | Phase 3 | Status: COMPLETED | Results posted: 2018-09-06